1. Home
  2. ATXS

as 10-24-2025 3:54pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Founded: 2008 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 676.1M IPO Year: 2015
Target Price: $30.00 AVG Volume (30 days): 4.1M
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.02 EPS Growth: N/A
52 Week Low/High: $3.56 - $12.55 Next Earning Date: 11-12-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -74.39%

ATXS Daily Stock ML Predictions

Share on Social Networks: